Ibrutinib and Idelalisib Target B Cell Receptor- but Not CXCL12/CXCR4-controlled Integrin-mediated Adhesion in Waldenström Macroglobulinemia

Overview

Journal Haematologica

Specialty Hematology

Date 2015 Dec 5

PMID 26635033

Citations 19

Authors

Martin F M de Rooij

Annemieke Kuil

Willem Kraan

Marie Jose Kersten

Steven P Treon

Steven T Pals

Marcel Spaargaren

Affiliations

Soon will be listed here.

Citing Articles

The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.

Lantermans H, Ma F, Kuil A, van Kesteren S, Yasinoglu S, Yang G Leukemia. 2024; 38(7):1570-1580.

PMID: 38454120 PMC: 11216997. DOI: 10.1038/s41375-024-02207-9.

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.

Alsadhan A, Chen J, Gaglione E, Underbayev C, Tuma P, Tian X Clin Cancer Res. 2023; 29(18):3612-3621.

PMID: 37227160 PMC: 10524232. DOI: 10.1158/1078-0432.CCR-22-3217.

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

Thus Y, de Rooij M, Beijersbergen R, Spaargaren M Bio Protoc. 2022; 12(21).

PMID: 36505024 PMC: 9711945. DOI: 10.21769/BioProtoc.4545.

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

de Rooij M, Thus Y, Swier N, Beijersbergen R, Pals S, Spaargaren M Nat Commun. 2022; 13(1):2136.

PMID: 35440579 PMC: 9018714. DOI: 10.1038/s41467-022-29835-y.

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahe B, Morel P Blood Adv. 2021; 5(9):2438-2446.

PMID: 33961019 PMC: 8114554. DOI: 10.1182/bloodadvances.2020003895.

References

Balabanian K, Lagane B, Pablos J, Laurent L, Planchenault T, Verola O . WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2004; 105(6):2449-57. DOI: 10.1182/blood-2004-06-2289. View

Spaargaren M, de Rooij M, Kater A, Eldering E . BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Oncogene. 2014; 34(19):2426-36. DOI: 10.1038/onc.2014.181. View

de Rooij M, Kuil A, Geest C, Eldering E, Chang B, Buggy J . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012; 119(11):2590-4. DOI: 10.1182/blood-2011-11-390989. View

Treon S, Xu L, Yang G, Zhou Y, Liu X, Cao Y . MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9):826-33. DOI: 10.1056/NEJMoa1200710. View

Advani R, Buggy J, Sharman J, Smith S, Boyd T, Grant B . Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2012; 31(1):88-94. PMC: 5505166. DOI: 10.1200/JCO.2012.42.7906. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning R . A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013; 122(7):1222-32. DOI: 10.1182/blood-2012-12-475111. View

Chang B, Francesco M, de Rooij M, Magadala P, Steggerda S, Huang M . Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013; 122(14):2412-24. PMC: 3790509. DOI: 10.1182/blood-2013-02-482125. View

Gopal A, Kahl B, de Vos S, Wagner-Johnston N, Schuster S, Jurczak W . PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370(11):1008-18. PMC: 4039496. DOI: 10.1056/NEJMoa1314583. View

10.

Flinn I, Kahl B, Leonard J, Furman R, Brown J, Byrd J . Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014; 123(22):3406-13. PMC: 4260978. DOI: 10.1182/blood-2013-11-538546. View

11.

Brown J, Byrd J, Coutre S, Benson D, Flinn I, Wagner-Johnston N . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22):3390-7. PMC: 4123414. DOI: 10.1182/blood-2013-11-535047. View

12.

Kahl B, Spurgeon S, Furman R, Flinn I, Coutre S, Brown J . A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014; 123(22):3398-405. PMC: 4260977. DOI: 10.1182/blood-2013-11-537555. View

13.

de Rooij M, Kuil A, Kater A, Kersten M, Pals S, Spaargaren M . Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015; 125(14):2306-9. PMC: 4416940. DOI: 10.1182/blood-2014-12-619163. View

14.

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

15.

Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez M . Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica. 2007; 92(5):635-42. DOI: 10.3324/haematol.10755. View